Asia is speedily becoming an increasingly popular destination for clinical trials. With a large pool of treatment-naive patients, high quality clinical infrastructure and talent, and lower costs. Most diseases commonly found in Western countries make Asia an attractive environment for conducting trials. Because government spend less on healthcare in many Asian countries, costs are relatively low compared to the US and Europe, therefore clinical trials enable patients to gain access to new new and innovative therapies. Asia also has several large, state-of-the-art clinical trial centres that are capable of enrolling a large numbers of patients whilst producing high-quality data. These centres are led by skilled investigators, many of whom have medical qualification obtained in the UK and USA. With increasing transparency in the regulatory environment, Asia is increasingly likely to become the preferred destination for clinical trials.